Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 18/20 | 0.72 |
| ▸ | MMP2 | P08253 | 4/20 | 0.72 |
| ▸ | MMP8 | P22894 | 2/20 | 0.72 |
| ▸ | MMP1 | P03956 | 1/20 | 0.72 |
| ▸ | COL2A1 | P02458 | 1/20 | 0.72 |
| ▸ | MMP12 | P39900 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22066283 | 0.86 | MMP13 (0.74) | MMP13MMP2MMP8MMP1COL2A1 | |
| SCHEMBL22066306 | 0.84 | MMP13 (1.00) | MMP13MMP2MMP8MMP1COL2A1 | |
| SCHEMBL22066290 | 0.84 | MMP13 (1.00) | MMP13MMP2MMP8MMP1COL2A1 | |
| SCHEMBL22066305 | 0.83 | MMP13 (1.00) | MMP13MMP2MMP8MMP1COL2A1 | |
| SCHEMBL22066285 | 0.83 | MMP13 (0.81) | MMP13MMP2MMP8MMP1COL2A1 | |
| SCHEMBL3583066 | 0.81 | MAPT (0.97) | MMP13CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL5190083 | 0.81 | MAPT (0.79) | MMP13CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL22066410 | 0.80 | MMP13 (1.00) | MMP13MMP2MMP8MMP1COL2A1 | |
| SCHEMBL22066282 | 0.80 | MMP13 (1.00) | MMP13MMP2MMP8MMP1COL2A1 | |
| SCHEMBL22067547 | 0.80 | MMP13 (1.00) | MMP13MMP2MMP8MMP1COL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181095-A1 | SELECTIVE MATRIX METALLOPROTEINASE-13 INHIBITORS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181095-A1 | SELECTIVE MATRIX METALLOPROTEINASE-13 INHIBITORS | MMP13, MMP17, MMP16 | MMP13 1/4885MMP2 16/4885MMP8 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.